An observational study in Asthma, Allergic Rhinitis and Cystic Fibrosis, sponsored by Boston Children's Hospital. Completed at 1 site in United States. Open to participants aged 6 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-22.
Sponsored by Boston Children's Hospital · Observational
This is a pilot cross-sectional study of measured transcutaneous CO-oximetry in children with inflammatory and non-inflammatory conditions.
Children and young adults age 6-24 with the following conditions: asthma, pneumonia, allergic rhinitis, cystic fibrosis, and well child (without inflammatory illness) will be recruited.
Subjects will be asked to complete a brief screening survey to determine if they meet inclusion criteria. Enrolled subjects will be asked to complete questionnaire forms to characterize their health, current symptoms, medications, and common exposures. Transcutaneous carboxyhemoglobin will be recorded.
This study is cross-sectional and will only require one visit coinciding with the clinical visit. Analysis will determine the pairwise differences in SpCO between conditions tested.
2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.
This study's enrollment of 59 is below the median of 203 across 688 observational studies indexed under Pneumonia.
Browse Pneumonia studies →Boston Children's Hospital is the lead sponsor of 598 studies on the registry; 151 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 18 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Age range 6-24years old. All genders, races, and ethnicities were sampled, provided they could complete the study requirements.
Exclusion Criteria:
Indicated by an asthma control test (ACT) score of \<20 and asthma symptoms of cough, wheeze, or chest tightness for more than 2 days in the prior 2 weeks, OR current asthma exacerbation indicated by the prescription of a short course (3-5 days) of systemic corticosteroids by treating provider at the time of visit.
Indicated by an ACT score of \>19, or spirometry results within 10% of year's best value (based on FEV1).
Indicated by an admission diagnosis of pneumonia with chest X-ray consistent with the diagnosis, based on attending radiologist's interpretation.
Indicated by a rhinitis control assessment test (RCAT) score of \>= 21.
Indicated by an RCAT score of \<21.
Indicated by treating physician's assessment of cystic fibrosis respiratory exacerbation within 24 hours of initial antibiotic therapy.
Indicated by diagnosis of cystic fibrosis with baseline symptoms and with spirometry results (based on FEV1) within 5% of year's best value.
Indicated by a negative history of any of the conditions characterizing the other groups.
SpCO comparison: uncontrolled asthma v. other groups
A pairwise comparison of mean SpCO will be performed between asthma exacerbation group and each other group, e.g., asthma exacerbation v. stable asthma, asthma exacerbation v. pneumonia, etc. An independent t-test will be used to determine statistical significance of the difference of means.
Time frame: Time of visit
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boston Children's Hospital